• OPEN AN ACCOUNT
Indian Indices
Sensex
83,919.71 897.96
( 1.08%)
Global Indices
Nasdaq
48,502.41 -615.65
(-1.25%)
Dow Jones
6,987.82 -209.01
(-2.90%)
Hang Seng
56,657.02 -2,787.19
(-4.69%)
Nikkei 225
10,369.59 -83.09
(-0.79%)
Forex
USD-INR
93.34 -0.08
(-0.09%)
EUR-INR
102.47 -0.06
(-0.06%)
GBP-INR
122.55 -0.48
(-0.39%)
JPY-INR
0.58 0.00
(-0.32%)

EQUITY - MARKET SCREENER

Tunwal E-Motors Ltd
Industry :  Automobiles - Motorcycles / Mopeds
BSE Code
ISIN Demat
Book Value()
77627
INE0OXV01027
21.7943281
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
TUNWAL
9.93
126.63
EPS(TTM)
Face Value()
Div & Yield %
2.21
2
0.46
 

crompton greaves ltd
Sun Pharma receives USFDA approval for ILUMYA® (tildrakizumab-asmn)
Oct 30,2026

Sun Pharmaceutical Industries announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA).

'FDA approval of ILUMYA for adults with active psoriatic arthritis represents another important innovative medicine milestone for Sun Pharma and builds on the established clinical experience of ILUMYA in plaque psoriasis,” said Rick Ascroft, North America CEO, Sun Pharma. 'As an IL-23 inhibitor administered exclusively by a healthcare provider, ILUMYA is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment or who may benefit from regular in-office care.'